Fosribnicotinamide (Standard)

Fosribnicotinamide (Standard) (β-Nicotinamide mononucleotide (Standard) ) is the analytical standard of Fosribnicotinamide (HY-F0004) . This product is intended for research and analytical applications. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity[1].

Product Specifications

CAS Number

[1094-61-7]

Product Name Alternative

β-Nicotinamide mononucleotide (Standard) ; β-NM (Standard) ; NMN (Standard)

UNSPSC

12352005

Target

Endogenous Metabolite; Reference Standards

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Purity

99.76

Smiles

O[C@@H]1[C@H](O)[C@@H](COP(O)([O-])=O)O[C@H]1[N+]2=CC=CC(C(N)=O)=C2

Molecular Formula

C11H15N2O8P

Molecular Weight

334.22

References & Citations

[1]Poddar SK, et al. Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule. Biomolecules. 2019;9 (1) :34. Published 2019 Jan 21.|[2]Lv H, et al. NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion [published online ahead of print, 2020 Nov 3]. Cell Metab. 2020; S1550-4131 (20) 30554-4.|[3]Li J, et al. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proc Natl Acad Sci U S A. 2019;116 (39) :19626-19634.|[4]Yoshino J, et al Nicotinamide mononucleotide, a key NAD (+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14 (4) :528-536.